Tarsus Pharmaceuticals, Inc. Common Stock (TARS) Financials
Key financial figures for Tarsus Pharmaceuticals, Inc. Common Stock (Q3 2026).
Tarsus reported record XDEMVY net product sales of $194.6 million for Q3 2026, up approximately 64% year over year, while a $632.2 million acquired in-process R&D charge from the iRenix and Alkeus deals drove a $668.3 million net loss. XDEMVY net product sales were $194.6 million versus $118.7 million in Q3 2025 (about 64% higher); the release attributes the growth to higher volume and improvements in gross-to-net discounts. Gross margin was approximately 93% in both periods. Acquired in-process R&D expense was $632.2 million ($81.0 million for iRenix and $551.2 million for Alkeus), expensed because the acquired programs have no alternative future use. Loss from operations was $662.1 million versus $14.5 million a year earlier. Figures are for Q3 2026, as Tarsus Pharmaceuticals Inc. reported them.
- Revenue
- $195M
- Net Income
- -$668M
- EPS
- $-14.40
- Total Assets
- $505M
- Operating Cash Flow
- -$6M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $195M | -$668M | -$14.40 | -340.29% | -$7M |
| Q2 FY2026 | $174M | -$19M | -$0.43 | -11.45% | $63M |
| Q1 FY2026 | $162M | -$7M | -$0.16 | -3.78% | -$30M |
| Q4 FY2025 | $152M | -$8M | -$0.20 | -5.26% | $13M |
| Q3 FY2025 | $119M | -$13M | -$0.30 | -12.24% | $16M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $451M | -$66M | -$1.59 | -15.72% | -$22M |
| FY2024 | $183M | -$116M | -$3.07 | -65.9% | -$85M |
| FY2023 | $17M | -$136M | -$4.62 | -820.53% | -$123M |
Frequently asked questions
What was Tarsus Pharmaceuticals Inc.'s revenue last quarter?
Tarsus Pharmaceuticals Inc. reported revenue of $194.6 million for Q3 FY2026, up 63.9% from the same period a year earlier.
Is Tarsus Pharmaceuticals Inc. profitable?
Not in its most recent reported period. Tarsus Pharmaceuticals Inc. reported a net loss of $668.3 million for Q3 FY2026, a net margin of -343.49% on revenue.
How has Tarsus Pharmaceuticals Inc.'s margin trended?
Operating margin was -340.29% in Q3 FY2026, compared with -12.24% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Tarsus Pharmaceuticals Inc. generate?
Tarsus Pharmaceuticals Inc. generated free cash flow of -$7.2 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Tarsus Pharmaceuticals, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.